Cost-effectiveness of irbesartan in diabetic nephropathy: A systematic review of published studies

Nephrology Dialysis Transplantation

Volumn 20, Issue , 2005, Pages 1103-1109

  Palmer, Andrew J ^a   Tucker, Daniel M D ^a   Valentine, William J ^a   Roze, Stéphane ^a   Gabriel, Sylvie ^b   Cordonnier, Daniel J ^c  

^a IQVIA   (United States)

^b SANOFI   (France)

^c GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

Cost effectiveness; Costs; Diabetes; End stage renal disease nephropathy; Hypertension; Irbesartan; Modelling

Indexed keywords

AMLODIPINE; IRBESARTAN;

ARTICLE; BELGIUM; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIABETIC NEPHROPATHY; DRUG COST; DRUG EFFICACY; FRANCE; GERMANY; HEALTH CARE COST; HEMODIALYSIS; HUMAN; HUNGARY; HYPERTENSION; INCIDENCE; ITALY; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LIFE EXPECTANCY; MEDLINE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SPAIN; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNITED KINGDOM; UNITED STATES;

ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; COST-BENEFIT ANALYSIS; DIABETIC NEPHROPATHIES; ECONOMICS, PHARMACEUTICAL; HUMANS; KIDNEY FAILURE, CHRONIC; LIFE EXPECTANCY; MARKOV CHAINS; TETRAZOLES;

EID: 20844449570     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfh802     Document Type: Article

References (29)

1. Ritz E, Rychlik I, Locatelli F, Halimi S. End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions. Am J Kidney Dis 1999; 34: 795-808
2. Rodby RA. Type II diabetic nephropathy: its clinical course and therapeutic implications. Semin Nephrol 1997; 17: 132-147
3. US Renal Data System. USRDS 2001 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2001.
4. UK Renal Registry. UK Renal Registry Report. UK Renal Registry, Bristol, 2002.
5. Stengel B, Billon S, van Dijk PC et al. Trends in the incidence of renal replacement therapy for end-stage renal disease in Europe, 1990-1999. Nephrol Dial Transplant 2003; 18: 1824-1833
6. Labeeuw M. Treatment of end stage renal failure by dialysis in Rhone-Alpes: changes over the period 1993-1999. Nephrologie 2001; 22: 161-166
7. Charra B, VoVan C, Marcelli D et al. Diabetes mellitus in Tassin, France: remarkable transformation in incidence and outcome of ESRD in diabetes. Adv Ren Replace Ther 2001; 8: 42-56
8. Jungers P, Choukroun G, Robino C et al. Epidemiology of end-stage renal disease in the Ile-de-France area: a prospective study in 1998. Nephrol Dial Transplant 2000; 15: 2000-2006
9. Lorenzo V, Martin UB. Epidemiologic analysis of the increase in terminal renal insufficiency associated with type 2 diabetes mellitus. Nefrologia 2000; 20 [Suppl 5]: 77-81
10. Perez GR, Rodriguez BP, Dall'Anesse C, Gomez CF, Valderrabano F. Pre-occupying increase in diabetes as cause for terminal kidney failure. Evaluation of treatment strategies. An Med Interna 2001; 18: 175-180
11. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860
12. Rodby RA, Chiou CF, Borenstein J et al. The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy. Clin Ther 2003; 25: 2103-2119
13. Palmer AJ, Annemans L, Roze S, Lamotte M, Rodby RA, Cordonnier D. An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy; cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian, and French settings. Nephrol Dial Transplant 2003; 18: 2059-2066
14. Palmer AJ, Annemans L, Roze S, Lamotte M, Rodby RA, Ritz E. Health economic consequences of the use of irbesartan in patients in Germany with type 2 diabetes, nephropathy and hypertension. Dtsch Med Wochenschr 2004; 129: 13-18
15. Palmer AJ, Borsos K, Annemans L et al. Cost-effectiveness analysis of irbesartan in the treatment of Type 2 diabetic patients complicated with hypertension and nephropathy. Hypertonia és Nephrologia 2004; 8
16. Palmer AJ, Annemans L, Roze S et al. Cost-effectiveness analysis of irbesartan in patients with type 2 diabetes, hypertension and nephropathy: the Italian perspective. Pharmacoeconomics 2004; 7: 41-55
17. Palmer AJ, Annemans L, Roze S, Lamotte M, Rodby RA, De Alvaro F. Cost-effectiveness of irbesartan in patients with type 2 diabetes, hypertension and nephropathy: a Spanish perspective. Nefrologia 2004; 24: 231-238
18. Palmer AJ, Annemans L, Roze S, Lamotte M, Rodby RA, Bilous RW. An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting. J Hum Hypertens 2004
19. Naimark D, Krahn MD, Naglie G, Redelmeier DA, Detsky AS. Primer on medical decision analysis: Part 5-Working with Markov processes. Med Decis Making 1997; 17: 152-159
20. Palmer AJ, Weiss C, Sendi PP et al. The cost-effectiveness of different management strategies for type I diabetes: a Swiss perspective. Diabetologia 2000; 43: 13-26
21. Bagust A, Hopkinson PK, Maier W, Currie CJ. An economic model of the long-term health care burden of Type II diabetes. Diabetologia 2001; 44: 2140-2155
22. Detsky AS, Redelmeier DA. Measuring health outcomes - putting gains into perspective. N Engl J Med 1998; 339: 402-404
23. Wright JC, Weinstein MC. Gains in life expectancy from medical interventions - standardizing data on outcomes. N Engl J Med 1998; 339: 380-386
24. Rodby RA, Firth LM, Lewis EJ. An economic analysis of captopril in the treatment of diabetic nephropathy. The Collaborative Study Group. Diabetes Care 1996; 19: 1051-1061
25. Schadlich PK, Brecht JG, Brunetti M, Pagano E, Rangoonwala B, Huppertz E. Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: economic evaluation of Ramipril Efficacy in Nephropathy (REIN) Study for Germany from the perspective of statutory health insurance. Pharmacoeconomics 2001; 19: 497-512
26. Ruggenenti P, Pagano E, Tammuzzo L, Benini R, Garattini L, Remuzzi G. Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies. Kidney Int 2001; 59: 286-294
27. Hendry BM, Viberti GC, Hummel S, Bagust A, Piercy J. Modelling and costing the consequences of using an ACE inhibitor to slow the progression of renal failure in type I diabetic patients. QJM 1997; 90: 277-282
28. Clark WF, Churchill DN, Forwell L, Macdonald G, Foster S. To pay or not to pay? A decision and cost-utility analysis of angiotensin-converting-enzyme inhibitor therapy for diabetic nephropathy. CMAJ 2000; 162: 195-198
29. Barnett AH, Bain SC, Bouter P et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004; 351: 1952-1961